EUCTR2008-007053-13-DE进行中（未招募）不适用
Doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase III zur Bestimmung der Wirksamkeit, Verträglichkeit und Sicherheit von intravesikal verabreichter Oxybutynin-Lösung bei Kindern/Jugendlichen mit neurogen bedingter Detrusorhyperaktivität
Grachtenhaus-Apotheke, Inh. Klaus Stegemann e. K.0 个研究点开始时间: 2009年6月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- written informed consent of patients and their legal representatives obtained
- •- patients of both gender
- •- patients aged 6-16 years inclusive, with a body weight of at least 15 kg to a maximum of 80 kg
- •- patients, who are performing clean (or sterile) intermittent catheterization (CIC)
- •- patients with detrusor hyperactivity confirmed by urodynamic measurement within the last 24 months and associated with a known neurological deficit
- •- patients with a leak-point-pressure of > 40 mm or patients with a leak-point-pressureof = 40 mm paralleled by incontinence within the catheterization inverval
- •- patients having failed to treatment with orally administered anticholinergic medication or in which treatment had been terminated due to adverse drug effects other than allergic reaction
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- patients with clinically significant abnormalities (unrelated to the trial indication), found at, or before randomization, as well as clinically significant findings during the physical examination, as determined by the investigator
- •- patients with clinically significant conditions which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the patient's ability to participate in the study
- •- patients with clinically significant laboratory abnormalities (based on investigator judgment) or laboratory values greater than 2 times the upper limit of normal range
- •- patients with a history of relevant orthostatic hypotension, fainting spells or blackouts
- •- patients with intolerance to the active ingredient oxybutynin
- •- patients with clinical pictures like polyuria or nycturia due to heart or renal failure, subvesical organic urinary output failure (e. g. prostataadenom, urethral stricture), constrictions (stenosis) in the area of the remaining urinary passage and gastrointestinal tract, acute angle-closure glaucoma (glaucoma) or complanate anterior chamber, fast and abnormal heartbeat (cardiac tachyarrhythmia), heavy colon aneurysma (toxic megacolon), heavy arteriosclerotic alteration of the celebral vessels (cerebrosclerosis), intestinal obstruction, hiatal hernia with reflux esophagitis, phlogistic colon ulcer, colon atresia
- •- patients with obstructive uropathy
- •- patients with Myasthenia gravis and / or severe Colitis ulcerosa
- •- patients with severe hydronephrosis greater than Grade 3; a renal ultrasound performed within 3 months prior to entering the study will be accepted as a baseline measurement if this assessment was performed while the patient was on a stable medication regimen
- •- patients with a known severe vesical-renal reflux higher than Grade 3 according to Parkkulainen
- •- patients with severe limitations in renal function according to laboratory chemical determination of renal function values
- •- patients with a pathological intraocular pressure – measured within 12 month prior to entering the study
- •- patients with a lifetime history of bladder neck surgery, bladder augmentation or permanently exteriorized bladder drainage procedures and those patients who have had any surgical procedure under general anaesthesia within 30 days prior to screening visit
- •- patients and their legal representatives with a significant psychiatric disorder (based on investigator discretion) that prevents their comprehension of consent and their ability to comply with the protocol
- •- patients on drug therapy, or non-drug therapy including electrostimulation for their neuropathic bladder initiated during the four weeks prior to screening or anticipated to initiate during the study
- •- patients who have a history of allergy/hypersensitivity (including drug and sulfa allergy) which is deemed relevant to the trial as judged by the investigator
- •- patients taking warfarin, ranitidine or cimetidine
- •- patients receiving CYP3A4 inhibiting pharmaceuticals or substances like Clomipramine, Itraconazole, Ketoconazole, Testosterone, Troleandomycin or rather CYP2D6 inhibiting pharmaceuticals like Dextromethorphan
- •- patients receiving anticholinergic or anticholinergic acting pharmaceuticals enhancing the function of oxybutynin, e. g. Amantadin and other Anti-Parkinson’s pharmaceuticals, Antihistamines, Neuroleptics, Chinidin, Digitalis, trizyclic Antidepressants, Atropi
研究者
相似试验
进行中（未招募）
不适用
Randomisierte, doppelblinde, placebokontrollierte Studie im Parallelgruppen-Design zur Untersuchung der Wirkung von Ginkgo-Spezialextrakt EGb 761® auf Lernprozesse bei gesunden Probandentersuchung der Wirkung von Ginkgo-Spezialextrakt EGb 761® auf Lernprozesse bei Gesunden.EUCTR2005-004476-20-DEDr. Willmar Schwabe GmbH & Co. KG
进行中（未招募）
不适用
Doppelblinde, randomisierte Placebo-kontrollierte crossover-Studie zur Erfassung des Effektes einer DPP-IV-Hemmung auf die Zahl und Funktion von Progenitorzellen sowie die Endothelfunktion von Patienten mit Diabetes mellitusFunctional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus - FINNjA-DMPatients with stable diabetes mellitus typ 2 and HbA1c between 7,0% and 10,0%EUCTR2008-007667-17-DEDekan des Fachbereichs Medizin der Johann Wolfgang Goethe-Universität Frankfurt/M.
进行中（未招募）
1 期
Double-blind, randomised, placebo-controlled trial of nicotine replacement therapy in pregnancy - Smoking, Nicotine and Pregnancy (SNAP) TrialSmoking during pregnancy Specifically smoking 5 or more cigarettes currently (i.e. whilst pregnant) and having smoked 10 or more cigarettes prior to pregnancy.EUCTR2004-002621-46-GBniversity of Nottingham1,050
招募中
1 期
Phase III clinical trial of ABCB5+ MSCs for the treatment of EBRecessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epidermolysis Bullosa (JEB)MedDRA version: 20.0Level: PTClassification code: 10014989Term: Epidermolysis bullosa Class: 100000004850CTIS2022-500266-10-00Rheacell GmbH & Co. KG163
尚未招募
不适用
Clinical Study for antioxidant effects of aroniaKCT0003013JBKLAB70